Therapeutic innovations in breast cancer.
Breast Neoplasms
/ chemistry
Cyclin-Dependent Kinase 4
/ antagonists & inhibitors
Cyclin-Dependent Kinase 6
/ antagonists & inhibitors
Female
Humans
Immunoconjugates
/ therapeutic use
Immunotherapy
/ methods
Poly(ADP-ribose) Polymerase Inhibitors
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Randomized Controlled Trials as Topic
Journal
Presse medicale (Paris, France : 1983)
ISSN: 2213-0276
Titre abrégé: Presse Med
Pays: France
ID NLM: 8302490
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
14
11
2018
revised:
13
03
2019
accepted:
04
04
2019
pubmed:
4
6
2019
medline:
18
12
2019
entrez:
2
6
2019
Statut:
ppublish
Résumé
Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.
Identifiants
pubmed: 31151842
pii: S0755-4982(19)30165-4
doi: 10.1016/j.lpm.2019.04.005
pii:
doi:
Substances chimiques
Immunoconjugates
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Protein Kinase Inhibitors
0
CDK4 protein, human
EC 2.7.11.22
CDK6 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1131-1137Informations de copyright
Copyright © 2019. Published by Elsevier Masson SAS.